LLY vs RYTM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and RYTM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and RYTM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Rhythm Pharmaceuticals is a Boston-based biopharmaceutical company focused on rare diseases of obesity caused by defects in the melanocortin-4 receptor (MC4R) pathway, the brain circuit that regulates hunger and energy balance. Its lead and only marketed product, IMCIVREE (setmelanotide), is an MC4R agonist first approved for certain rare genetic obesity disorders and Bardet-Biedl syndrome, and in March 2026 the FDA approved it for acquired hypothalamic obesity (weight gain caused by damage to the hypothalamus, often after brain tumors or their treatment). The company is also advancing bivamelagon, a next-generation oral MC4R agonist, and other early programs aimed at broadening its franchise across rare and anatomically driven forms of obesity.

Full RYTM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• RYTM drivers: Acquired hypothalamic obesity launch; Existing genetic obesity and BBS base.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For RYTM, rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company.

Pick LLY if you believe its drivers more; RYTM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and RYTM guides.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

RYTM. As of July 2026 Rhythm trades at a market cap near $8 billion against roughly $220 million in trailing revenue, a rich multiple that reflects expectations for rapid growth from the acquired hypothalamic obesity launch. The company is not profitable, funding launch and pipeline spending from its cash balance, which management has said should support operations for at least the next 24 months. These are approximate figures referenced to the July 2026 date and will change as new results are reported.

Headline figures (approximate, early 2026): LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify); RYTM shows revenue (ttm) ~$220M, q1 2026 net product revenue ~$60.1M, q1 2026 net loss ~$55.6M, market cap ~$7.8B.

LLY and RYTM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and RYTM exposure against your real portfolio. It is not an investment adviser.